{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:18:00Z","timestamp":1769203080629,"version":"3.49.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.cld.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:06:33Z","timestamp":1567242393000},"page":"607-623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach"],"prefix":"10.1016","volume":"23","author":[{"given":"Beshoy","family":"Yanny","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Winters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sammy","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.23500","article-title":"Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study","volume":"51","author":"Jepsen","year":"2010","journal-title":"Hepatology"},{"issue":"6260","key":"10.1016\/j.cld.2019.07.001_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmj.282.6260.263","article-title":"A\u00a020-year prospective study of cirrhosis","volume":"282","author":"Saunders","year":"1981","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"10.1016\/j.cld.2019.07.001_bib4","first-page":"42","article-title":"Liver cirrhosis in Italy. A multicentre study on presenting modalities and the impact on health care resources. National Project on Liver Cirrhosis Group","volume":"23","author":"Coltorti","year":"1991","journal-title":"Ital J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01320309","article-title":"Survival and prognostic indicators in compensated and decompensated cirrhosis","volume":"31","author":"D'Amico","year":"1986","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.cld.2019.07.001_bib6","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.21586","article-title":"Value of the critical flicker frequency in patients with minimal hepatic encephalopathy","volume":"45","author":"Romero-Gomez","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0168-8278(00)80243-3","article-title":"Screening of subclinical hepatic encephalopathy","volume":"32","author":"Groeneweg","year":"2000","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.07.001_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jhep.2007.02.022","article-title":"Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy","volume":"47","author":"Sharma","year":"2007","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2019.07.001_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1440-1746.2001.02388.x","article-title":"Auditory P300 event-related potentials and number connection test for evaluation of subclinical hepatic encephalopathy in patients with cirrhosis of the liver: a follow-up study","volume":"16","author":"Saxena","year":"2001","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2019.07.001_bib10","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.3748\/wjg.v10.i16.2397","article-title":"Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China","volume":"10","author":"Li","year":"2004","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2019.07.001_bib11","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1111\/j.1572-0241.2008.02102.x","article-title":"Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts","volume":"103","author":"Riggio","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2019.07.001_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s11547-017-0770-6","article-title":"Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification","volume":"122","author":"Fonio","year":"2017","journal-title":"Radiol Med"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.clinthera.2016.03.033","article-title":"Natural history of patients taking rifaximin-alpha for recurrent hepatic encephalopathy and risk of future overt episodes and mortality: a post-hoc analysis of clinical trials data","volume":"38","author":"Bannister","year":"2016","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.cld.2019.07.001_bib14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1038\/ajg.2011.157","article-title":"The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers","volume":"106","author":"Bajaj","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0168-8278(99)80144-5","article-title":"Prognostic significance of hepatic encephalopathy in patients with cirrhosis","volume":"30","author":"Bustamante","year":"1999","journal-title":"J\u00a0Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2019.07.001_bib16","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/lt.23981","article-title":"Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation","volume":"20","author":"Wong","year":"2014","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.cld.2019.07.001_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40273-018-0641-6","article-title":"Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin","volume":"36","author":"Neff","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.cld.2019.07.001_bib18","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.cgh.2012.05.016","article-title":"In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib19","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep4.1137","article-title":"Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis","volume":"2","author":"Chirapongsathorn","year":"2018","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.cld.2019.07.001_bib20","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.cgh.2016.04.009","article-title":"Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study","volume":"14","author":"Tapper","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.mayocp.2015.03.003","article-title":"Refining the ammonia hypothesis: a physiology-driven approach to the treatment of hepatic encephalopathy","volume":"90","author":"Tapper","year":"2015","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1016\/j.cld.2019.07.001_bib22","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2165\/00003495-200060060-00008","article-title":"Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management","volume":"60","author":"Gerber","year":"2000","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib23","first-page":"142","article-title":"Hepatic encephalopathy: an update on the pathophysiology and therapeutic options","volume":"5","author":"Elwir","year":"2017","journal-title":"J\u00a0Clin Transl Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2019.07.001_bib24","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1056\/NEJMra1600561","article-title":"Hepatic encephalopathy","volume":"375","author":"Wijdicks","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2019.07.001_bib25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.1840060424","article-title":"Evidence for the role of ammonia in the intracerebral transfer and metabolism of tryptophan","volume":"6","author":"Grippon","year":"1986","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2019.07.001_bib26","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1053\/jhep.2002.31250","article-title":"Hepatic encephalopathy\u2013definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998","volume":"35","author":"Ferenci","year":"2002","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib27","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/gastro\/gox013","article-title":"Hepatic encephalopathy","volume":"5","author":"Ferenci","year":"2017","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2019.07.001_bib28","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jceh.2014.06.005","article-title":"Diagnosis of minimal hepatic encephalopathy","volume":"5","author":"Weissenborn","year":"2015","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2019.07.001_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/ajg.2015.377","article-title":"Diagnosis of minimal hepatic encephalopathy using Stroop EncephalApp: a multicenter US-based, norm-based study","volume":"111","author":"Allampati","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2019.07.001_bib30","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.26309","article-title":"The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy","volume":"58","author":"Bajaj","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib31","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mayocp.2013.11.009","article-title":"Management of hepatic encephalopathy in the hospital","volume":"89","author":"Leise","year":"2014","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.cld.2019.07.001_bib32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","article-title":"Rifaximin treatment in hepatic encephalopathy","volume":"362","author":"Bass","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2019.07.001_bib33","first-page":"666","article-title":"Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy","volume":"21","author":"Abid","year":"2011","journal-title":"J\u00a0Coll Physicians Surg Pak"},{"key":"10.1016\/j.cld.2019.07.001_bib34","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/tid.12031","article-title":"Molecular Adsorbent Recirculating System (MARS((R)) ) removal of piperacillin\/tazobactam in a patient with acetaminophen-induced acute liver failure","volume":"15","author":"Ruggero","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cld.2019.07.001_bib35","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/hep.26314","article-title":"Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy","volume":"57","author":"Laleman","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2019.07.001_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5009\/gnl15419","article-title":"Evaluation and management of hepatic encephalopathy: current status and future directions","volume":"10","author":"Suraweera","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.cld.2019.07.001_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/IJGM.S81878","article-title":"Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy","volume":"8","author":"Saab","year":"2015","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.cld.2019.07.001_bib38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1440-1746.2012.07186.x","article-title":"Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose","volume":"27","author":"Sharma","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib39","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.25507","article-title":"Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis","volume":"55","author":"Bajaj","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib40","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.cgh.2013.12.021","article-title":"Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy","volume":"12","author":"Mullen","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MCG.0b013e318231faae","article-title":"Durability of rifaximin response in hepatic encephalopathy","volume":"46","author":"Neff","year":"2012","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib42","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1345\/aph.1R146","article-title":"Combination therapy for the treatment and prevention of hepatic encephalopathy","volume":"46","author":"Mohammad","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.cld.2019.07.001_bib43","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/hep.23216","article-title":"Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy","volume":"50","author":"Bajaj","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2019.07.001_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2036.2009.04211.x","article-title":"Review article: the modern management of hepatic encephalopathy","volume":"31","author":"Bajaj","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2019.07.001_bib45","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1097\/01.aids.0000192076.03443.6d","article-title":"Neurological and neuropsychiatric syndromes associated with liver disease","volume":"19","author":"Weissenborn","year":"2005","journal-title":"AIDS"},{"issue":"8","key":"10.1016\/j.cld.2019.07.001_bib46","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.clinbiochem.2005.04.013","article-title":"Evaluation of plasma ammonia levels in patients with acute liver failure and chronic liver disease and its correlation with the severity of hepatic encephalopathy and clinical features of raised intracranial tension","volume":"38","author":"Kundra","year":"2005","journal-title":"Clin Biochem"},{"issue":"6","key":"10.1016\/j.cld.2019.07.001_bib47","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/hep.21838","article-title":"Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure","volume":"46","author":"Bernal","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib48","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MCG.0b013e318299c789","article-title":"Safety of ornithine phenylacetate in cirrhotic decompensated patients: an open-label, dose-escalating, single-cohort study","volume":"47","author":"Ventura-Cots","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib50","first-page":"105","article-title":"Treatment of hyperammonemia in liver failure","volume":"17","author":"Jover-Cobos","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.cld.2019.07.001_bib51","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jgh.12142","article-title":"l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials","volume":"28","author":"Bai","year":"2013","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.mcna.2009.03.009","article-title":"Hepatic encephalopathy: pathophysiology and emerging therapies","volume":"93","author":"Sundaram","year":"2009","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.cld.2019.07.001_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1475-2891-12-74","article-title":"A\u00a0systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy","volume":"12","author":"Chavez-Tapia","year":"2013","journal-title":"Nutr J"},{"key":"10.1016\/j.cld.2019.07.001_bib54","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jvir.2012.05.046","article-title":"Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience","volume":"23","author":"Mukund","year":"2012","journal-title":"J\u00a0Vasc Interv Radiol"},{"key":"10.1016\/j.cld.2019.07.001_bib55","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/apt.12771","article-title":"Improvement in survival associated with embolisation of spontaneous portosystemic shunt in patients with recurrent hepatic encephalopathy","volume":"39","author":"An","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2019.07.001_bib56","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/hep.510290309","article-title":"Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration","volume":"29","author":"Clemmesen","year":"1999","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2019.07.001_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.jcbfm.9600168","article-title":"Persistent arterial hyperammonemia increases the concentration of glutamine and alanine in the brain and correlates with intracranial pressure in patients with fulminant hepatic failure","volume":"26","author":"Tofteng","year":"2006","journal-title":"J\u00a0Cereb Blood Flow Metab"},{"key":"10.1016\/j.cld.2019.07.001_bib58","doi-asserted-by":"crossref","first-page":"479","DOI":"10.12659\/AOT.898901","article-title":"Ammonia level and mortality in acute liver failure: a single-center experience","volume":"21","author":"Niranjan-Azadi","year":"2016","journal-title":"Ann Transplant"},{"issue":"12","key":"10.1016\/j.cld.2019.07.001_bib59","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.cgh.2015.06.039","article-title":"Covert and overt hepatic encephalopathy: diagnosis and management","volume":"13","author":"Patidar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2019.07.001_bib60","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/liv.12956","article-title":"Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy","volume":"35","author":"Pereira","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2019.07.001_bib61","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.2214\/ajr.169.6.9393198","article-title":"Encephalopathy after transjugular intrahepatic portosystemic shunting: analysis of incidence and potential risk factors","volume":"169","author":"Zuckerman","year":"1997","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.cld.2019.07.001_bib62","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1051-0443(98)70296-9","article-title":"Transjugular intrahepatic portosystemic shunt constraining stent for the treatment of refractory postprocedural encephalopathy: a simple design utilizing a Palmaz stent and Wallstent","volume":"9","author":"Forauer","year":"1998","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"1 Pt 1","key":"10.1016\/j.cld.2019.07.001_bib63","first-page":"46","article-title":"Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study","volume":"20","author":"Sanyal","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib64","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/BF02282344","article-title":"Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: incidence and risk factors","volume":"41","author":"Riggio","year":"1996","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2019.07.001_bib65","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.gastro.2003.11.016","article-title":"Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study","volume":"126","author":"Bureau","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.07.001_bib66","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1440-1746.2010.06400.x","article-title":"Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stents versus bare stents: a meta-analysis","volume":"25","author":"Yang","year":"2010","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib67","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cld.2011.12.008","article-title":"Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt","volume":"16","author":"Riggio","year":"2012","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2019.07.001_bib68","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.dld.2009.11.007","article-title":"Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines?","volume":"42","author":"Riggio","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003044","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy","author":"Als-Nielsen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2019.07.001_bib70","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.28598","article-title":"Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis","volume":"64","author":"Gluud","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib71","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1440-1746.2011.06663.x","article-title":"Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review","volume":"26","author":"Bai","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib72","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/j.1478-3231.2010.02293.x","article-title":"Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration","volume":"30","author":"Guevara","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2019.07.001_bib73","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study","volume":"42","author":"Riggio","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib74","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2214\/AJR.09.2968","article-title":"Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft","volume":"193","author":"Fanelli","year":"2009","journal-title":"AJR Am J Roentgenol"},{"issue":"Suppl 3","key":"10.1016\/j.cld.2019.07.001_bib75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1034\/j.1478-3231.23.s.3.10.x","article-title":"Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure","volume":"23","author":"Catalina","year":"2003","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2019.07.001_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2005.01.032","article-title":"Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis","volume":"43","author":"Sen","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib77","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/cc4985","article-title":"Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure","volume":"10","author":"Laleman","year":"2006","journal-title":"Crit Care"},{"key":"10.1016\/j.cld.2019.07.001_bib78","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/hep.26185","article-title":"Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial","volume":"57","author":"Ba\u00f1ares","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2019.07.001_bib79","series-title":"Cirrhosis: a practical guide to management","first-page":"105","article-title":"Hepatic encephalopathy","author":"Amodio","year":"2015"},{"key":"10.1016\/j.cld.2019.07.001_bib80","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2147\/TCRM.S4443","article-title":"Current trends in the treatment of hepatic encephalopathy","volume":"5","author":"Mcguire","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"10.1016\/j.cld.2019.07.001_bib81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4292\/wjgpt.v1.i2.54","article-title":"Hepatic encephalopathy therapy: an overview","volume":"1","author":"Riggio","year":"2010","journal-title":"World J Gastrointest Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.cld.2019.07.001_bib82","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ajg.2013.219","article-title":"A\u00a0randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy","volume":"108","author":"Sharma","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib83","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial","volume":"23","author":"Pedretti","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib84","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/MEG.0b013e328302f470","article-title":"Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis","volume":"20","author":"Jiang","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib85","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-4615-1989-8_13","article-title":"Neomycin reduces the intestinal production of ammonia from glutamine","volume":"368","author":"Hawkins","year":"1994","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.cld.2019.07.001_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/gut.23.1.1","article-title":"Treatment of hepatic encephalopathy with metronidazole","volume":"23","author":"Morgan","year":"1982","journal-title":"Gut"},{"key":"10.1016\/j.cld.2019.07.001_bib87","first-page":"703","article-title":"Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy","volume":"19","author":"Shavakhi","year":"2014","journal-title":"J\u00a0Res Med Sci"},{"key":"10.1016\/j.cld.2019.07.001_bib88","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2019.07.001_bib89","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.cgh.2013.11.006","article-title":"Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial","volume":"12","author":"Lunia","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2019.07.001_bib90","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ajg.2012.113","article-title":"Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy","volume":"107","author":"Agrawal","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib91","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clinre.2015.03.008","article-title":"Probiotics can improve the clinical outcomes of hepatic encephalopathy: an update meta-analysis","volume":"39","author":"Zhao","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cld.2019.07.001_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJM195801092580201","article-title":"Management of hepatocerebral intoxication","volume":"258","author":"Manning","year":"1958","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2019.07.001_bib93","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1001\/jamainternmed.2014.4746","article-title":"Lactulose vs polyethylene glycol 3350: electrolyte solution for treatment of overt hepatic encephalopathy. The HELP randomized clinical trial","volume":"174","author":"Rahimi","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cld.2019.07.001_bib94","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1590-8658(00)80027-4","article-title":"Flumazenil in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double blind randomized placebo controlled study","volume":"32","author":"Laccetti","year":"2000","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2019.07.001_bib95","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/lt.24440","article-title":"Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy","volume":"22","author":"Lynn","year":"2016","journal-title":"Liver Transpl"},{"issue":"9","key":"10.1016\/j.cld.2019.07.001_bib96","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1365-2036.2010.04448.x","article-title":"Clinical trial: oral zinc in hepatic encephalopathy","volume":"32","author":"Takuma","year":"2010","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326119300443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:55:44Z","timestamp":1761069344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326119300443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":96,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1089326119300443"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2019.07.001","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}